Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 6:41 PM
Ignite Modification Date: 2025-12-24 @ 6:41 PM
NCT ID: NCT00366457
Eligibility Criteria: Inclusion Criteria: * Previously untreated patients with unresectable or metastatic adenocarcinoma of the pancreas * ECOG Performance Status 0-2 * 18 years of age or older * Radiographically measurable disease * Expected survival of at least 4 months * Creatinine of \</= 2.0 * Adequate hepatic function * Adequate hematopoietic function * Use of effective means of contraception in subjects of child-bearing potential Exclusion Criteria: * Warfarin anticoagulation * Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor * Coexistent malignant disease * Current or recent (within 4 weeks) participation in a clinical trial * Pregnancy * Documented invasion of adjacent organs or major blood vessels * Blood pressure of \> 150/100mmHg * Unstable angina * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or stroke within 6 months * Clinically significant peripheral vascular disease * Evidence of bleeding diathesis of coagulopathy * Presence of CNS or brain metastases * Major surgical procedure, open biopsy, or significant traumatic event within 28 days * Minor surgical procedures, fine needle aspirations or core biopsies within 7 days * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months * Serious non-healing wound, ulcer or bone fracture
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00366457
Study Brief:
Protocol Section: NCT00366457